Wegovy and Ozempic, both GLP-1 agonists, have taken the world by storm, providing a simple way to lose weight without changing our lifestyle. A new report in Science helps us understand what we do not know: the known unknowns of obesity. Let me summarize.
Ozempic, a drug indicated for Type II diabetes, has become the latest weight-loss darling. Not since ivermectin has a drug gained so much interest from its off-label uses. Let’s take a deeper look at the science and a regulatory conundrum.